TEVA PHARMACEUTICAL INDUSTRIES LTD Uncategorized Contracts & Agreements
18 Contracts & Agreements
- Letter Agreement, dated as of February 11, 2022, between Teva Pharmaceuticals Europe and Richard Daniell (Filed With SEC on February 12, 2024)
- Deferred Prosecution Agreement, dated August 21, 2023 (Filed With SEC on August 24, 2023)
- Letter Agreement, dated as of February 8, 2023, between Teva Pharmaceutical Industries Ltd. and Eric Drap (Filed With SEC on May 10, 2023)
- Letter Agreement, dated as of December 27, 2022, between Teva Pharmaceutical Industries and Eric Drape (Filed With SEC on February 10, 2023)
- Letter Agreement, dated November 21, 2022, between Teva Pharmaceutical Industries Limited and Kre Schultz (Filed With SEC on February 10, 2023)
- Appointment Letter, dated as of July 27, 2021, of Sven Dethlefs (Filed With SEC on February 9, 2022)
- Appointment Letter, dated as of July 27, 2021, of Mark Sabag (Filed With SEC on February 9, 2022)
- Form Special Award Letter applicable to selected 2017 grants made to Gianfranco Nazzi and Brendan OGrady (Filed With SEC on February 21, 2020)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 21, 2020)
- Letter Agreement, dated as of May 8, 2012, between Teva Pharmaceutical Industries Limited and Dr. Michael Hayden (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of June 2017, between Teva Pharmaceutical Industries Limited and Mark Sabag (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of July 28, 2015, between Teva Pharmaceutical Industries Limited and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of November 7, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of December 1, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of February 21, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of April 26, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of September 19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)
- Letter Agreement, dated as of July 19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)
